66849-11-4

Upstream product

• 57009-13-9 methyl-2-isopropoxybenzoate 
• 119-36-8 methyl salicylate 
• 13205-46-4 4-isopropoxybenzoic acid 
• 63635-26-7 2-isopropoxybenzoic acid 

Downstream Products

• 69819-13-2 2-isopropoxy-N-(5-nitro-thiazol-2-yl)-benzamide 
• 938193-71-6 N-(4-cyano-3-trifluoromethyl-phenyl)-2-isopropoxy-benzamide 
• 1334308-65-4 C₂₄H₃₉N₃O₂ 
• 318730-48-2 (6R,7R)-7-(2-Isopropoxy-benzoylamino)-7-methoxy-3-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-5-oxa-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 4-benzhydryloxycarbonyl-benzyl ester 
• 318730-14-2 (6R,7R)-7-(2-Isopropoxy-benzoylamino)-7-methoxy-3-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-5-oxa-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 168163-02-8 (Z)-[4,4-difluoro-1-[4-(2-isopropoxybenzoyl)amino]benzoyl-2,3,4,5-tetrahydro-1H-1-benzazepin-5-ylidene]acetic acid 
• 168162-78-5 methyl (Z)-[4,4-difluoro-1-[4-(2-isopropoxybenzoyl)amino]benzoyl-2,3,4,5-tetrahydro-1H-1-benzazepin-5-ylidene]acetate 
• 206855-17-6 (6R,7R)-7-(2-Isopropoxy-benzoylamino)-7-methoxy-3-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-5-oxa-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 168626-59-3 2-isopropyloxy-4'-[(5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide 
• 63746-15-6 2-(2-isopropoxy-phenyl)-4-oxo-4H-benzo[d][1,3]oxazine-6-carboxylic acid 
• 1622869-28-6 C₂₄H₂₁F₃N₂O₄ 
• 1622869-18-4 C₂₄H₂₄N₂O₃ 

Relevant academic research and scientific papers

Metal-free Synthesis of Spiro-2,2′-benzo[b]furan-3,3′-ones via PhI(OAc)2-Mediated Cascade Spirocyclization

Treating the benzyl protected 3-hydroxy-1,3-bis(2-hydroxyphenyl)prop-2-en-1-ones solely with PhI(OAc)2 (PIDA) in DCE at room temperature readily furnished the seldom studied spiro-2,2′-benzo[b]furan-3,3′-ones in satisfactory to excellent yields. The hypervalent iodine reagent enables the metal-free cascade spirocyclization resulting in the dual oxidative C?O bond formation. (Figure presented.).

Modulators (inhibitors/ activators) of histone acetyltransferases

Disclosed are compounds of the formulae: and method of using the compounds to treat cancer, AIDS, HIV infection, and asthma.

Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1a receptor by introduction of alkoxy groups

A series of compounds structurally related to 4′-[(4,4-difluoro-5- methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-yl)carbonyl]benzanilide were synthesized and evaluated for arginine vasopressin (AVP) antagonistic activity. Compounds with alkoxy groups (especially ethoxy group) at the 2′-position of benzanilide possessed potent affinity and selectivity for the V1A receptor versus V2 receptor. Further study has shown that the introduction of 4,4-dimethylaminopiperidino and morpholino groups at carbonylmethylene exhibited more potent affinity and selectivity for V 1A receptors. Consequently, we found that the (Z)-4′-({4,4- Difluoro-5-[(4-dimethylaminopiperidino) carbonylmethylene]-2,3,4,5-tetrahydro- 1H-1-benzoazepin-1-yl}carbonyl)-2-ethoxybenzanilide monohydrochloride (8d) and the (Z)-4′-[(4,4-Difluoro-5-morpholinocarbamoylethylene-2,3,4,5- tetrahydro-1H-1-benzoazepin-1-yl)carbonyl]-2-ethoxybenzanilide (8q) exhibited potent and selective V1A receptor antagonist activity. The synthesis and pharmacological properties of these compounds are detailed in this paper.

Nonpeptide arginine vasopressin antagonists for both V(1A) and V2 receptors: Synthesis and pharmacological properties of 4'-(1,4,5,6- tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanilide derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d] [1]benzoazepine-6-carbonyl)benzanilide derivatives

Arginine vasopressin (AVP) has a dual action mainly in the periphery, i.e., vasoconstriction and water reabsorption via V(1A) and V2 receptors; it may play a role in a number of diseases, including congestive heart failure (CHF), hypertension, renal disease, edema, and hyponatremia. We have attempted to develop a new series of orally active AVP antagonists for both V(1A) and V2 receptors based on the hypothesis that the blockade of both V(1A) and V2 receptors might be beneficial to CHF patients. In this report, a series of compounds structurally related to 4'-(1,4,5,6- tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanilide and 4'-(5,6- dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilide were synthesized and examined for AVP antagonist activity for both V(1A) and V2 receptors. As a result, it was found that the 4'-(1,4,5,6- tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)-2-phenylbenzanilide derivatives showed potent binding affinity for both V(1A) and V2 receptors. Especially, 4'-(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6- carbonyl)-2-phenylbenzanilide monohydrochloride (18, YM087=conivaptan hydrochloride) exhibited potent binding affinity and AVP antagonist activity, after intravenous administration, for both V(1A) and V2 receptors. Furthermore, YM087 exhibited the most potent oral activity for the V2 receptor. Details of the synthesis and pharmacological properties of this series are presented.

Ester composition

The invention relates to a method for preparing an ester composition in which at least one activated phenolic ether group of a molecule is reacted with at least one haloformyl group of another molecule.